Navigation Links
New therapies increase survival rates in post-transplant liver cancer patients
Date:3/25/2010

effects were due to a direct impact of the drug on tumor or more on liver transplant in general, the research team conducted a similar analysis on non-HCC patients. While anti-CD25 induction was again associated with a trend toward improved survival, sirolimus showed a trend toward lower rates of survival in non-HCC recipients, confirming the specificity of its beneficial impact to cancer patients.

"Of all protocols, sirolimus-based immunosuppression was the only one associated with an improved post-transplantation survival specific to HCC patients, further reinforcing the clinical evidence of its anti-cancer properties," Dr. Toso concluded. "The use of anti-CD25 antibodies demonstrated similar trends to improved survival in both HCC and non-HCC patients. These observations, together with previous reports combining anti-CD25 antibody induction and delayed introduction of CNIs, speak in favor of the use of this drug after liver transplantation in general."

He adds, "Like any potent immunosuppressive drug, sirolimus is linked to a potential for development of numerous side effects. In general however, we believe that these side effects are relatively minor and easy to manage, and that the data revealed by the present study justify a broader use of protocols including sirolimus after liver transplantation for patients with HCC."

In another recent study on hepatocellular carcinoma, researchers from Seoul Veterans Hospital compared hepatic resection (HR) to radiofrequency ablation (RFA) to treat patients with very early-stage HCC, defined as asymptomatic solitary HCC less than 2cm. Very early stage HCC can be an ideal indication for HR because of the low potential risk of microscopic seeding. According to AASLD guidelines, HR is the treatment of choice for patients with very early stage HCC.

Researchers compared HR and percutaneous RFA for the treatment of compensated cirrhotic patients with very early stage HCC using a Markov model
'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study evaluates costs and benefits associated with new colon cancer therapies
2. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
3. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
6. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
7. MSU researcher linking breast cancer patients with alternative therapies
8. Translational Regenerative Medicine Forum sets stage for accelerating therapies to patients
9. Kids Use of Alternative Therapies Often Mimics Parents
10. Med students say conventional medicine would benefit by integrating alternative therapies
11. China a rising star in regenerative medicine despite world skepticism of stem cell therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... NY (PRWEB) October 26, 2014 BioSkinLaser.Com, ... announces the most advanced and improved laser treatments for ... and safe treatments like the lip enhancement treatment ... keeping with specific focus areas of each customer. , ... cellulite reduction NYC . The company cited that ...
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival ... (Alimta), after his combination drug therapy became too toxic. ... just posted on the Surviving Mesothelioma website. , ... in Japan suggests that “maintenance therapy” with pemetrexed may ... cannot tolerate higher doses of cisplatin. , “Although ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2
... flies. And it,s not just because they breed like ... and developmental biology by breeding and studying fruit flies (Drosophila ... important research animals because they reproduce quickly and, well, fruitfully; ... many genes and proteins with humans. Now there,s a ...
... study into Staphylococcus aureus , the bacterium which ... bacteria have developed a strategy of hiding within host ... many antibacterial treatments. The research, published by EMBO ... to adapt to their environmental conditions, lie dormant inside ...
... 700,000 for each of the 2011 prizes, of which CHF ... CHF 100,000 for their personal use. The prize ... be of considerable significance for medicine. Stefan Jentsch is ... his work on small protein modifiers and their role in ...
... , WEDNESDAY, Jan. 26 (HealthDay News) -- Screening ... higher in the United States among young black and ... explain why black and Hispanic women have higher reported ... Researchers who analyzed data from more than 40,000 visits ...
... conducted at Sahlgrenska University Hospital in Gothenburg and at ... of 18 and 65. Half the group was randomly ... half to maintain their usual lifestyle. Both groups ... group increased their physical activity on their own, but ...
... , TUESDAY, Jan. 25 (HealthDay News) -- Longevity isn,t increasing ... other developed countries, says a new report that points a ... 25 years, U.S. life expectancy at age 50 has increased, ... countries studied, including Japan and Australia, notes the report from ...
Cached Medicine News:Health News:Zebrafish popular with researchers 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:2011 Louis-Jeantet Prize for Medicine 2Health News:2011 Louis-Jeantet Prize for Medicine 3Health News:2011 Louis-Jeantet Prize for Medicine 4Health News:2011 Louis-Jeantet Prize for Medicine 5Health News:More Screenings May Explain Higher Chlamydia Rates Among Minorities 2Health News:Smoking, Obesity Slowing U.S. Life Expectancy Gains: Report 2Health News:Smoking, Obesity Slowing U.S. Life Expectancy Gains: Report 3
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... CITY, Calif., Oct. 21, 2014 Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... Second quarter overview: , Revenues of ... , Diluted EPS of $0.24, up 33% over ... , Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
... California, 23 May 2007 - The antidepressant duloxetine,hydrochloride ... patients who did not respond, or responded only,partially, ... regardless of whether those patients were,switched from an ... was presented today at the American Psychiatric,Association’s 160 ...
... - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company that ... today announced that clinical findings for three,different TAP ... to be,reported at the 43rd American Society of ... 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract #1042) ...
Cached Medicine Technology:In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3
... Featuring an expanded database containing ... new identification cards, VITEK 2 Compact ... minimum amount of time (2 to ... majority of microorganisms that contaminate production ...
... Horizon Cardiology Hemo is a comprehensive ... for the cath lab. Patient ... cardiac images and procedural information all ... patient record, eliminating repetitive data entry. ...
... generation product is a patient monitoring system ... parameters, sensed at the tissue level, reflecting ... tissue by low power light and detects ... tissue. The light is guided to the ...
PowerMed is a billing software....
Medicine Products: